About Calliditas Therapeutics AB (CALT)

The current price per share for Calliditas Therapeutics AB (CALT) is $40. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

For Calliditas Therapeutics AB (CALT), the 52-week high is $43, which is 7.5% from the current price. The 52-week low is $15.25, the current price is 162.3% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

Calliditas Therapeutics AB (CALT) has shown an average price growth of -6.03% over the past three years. It has received a score of 85 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Calliditas Therapeutics AB as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

As of the latest data, Calliditas Therapeutics AB (CALT) has a year-to-date price change of 60.01%. Over the last three months, the change has been -1.33%. Over the past six months, the figure is 86.05%.

Calliditas Therapeutics AB (CALT) has a net income of -$466.18M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.62% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -5.63% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 50.32%, providing insight into the company's sales performance and growth. The gross profit is $1.13B. Operating income is noted at -$384.4M. Furthermore, the EBITDA is $342.3M.

Calliditas Therapeutics AB (CALT) has a market capitalization of $723.12M. The average daily trading volume is 2.5K, indicating the stock's liquidity and investor engagement.